Published December 2008 | Version v1
Report

RI-production plan using JMTR

  • 1. Japan Atomic Energy Agency, Oarai Research and Development Center, Oarai, Ibaraki (Japan)

Description

At Oarai Research and Development Center, Japan Atomic Energy Agency (JAEA) is advancing the plan of refurbishing Japan Materials Testing Reactor (JMTR) to start the operation from FY 2011. At the JMTR, the iridium-192 (192Ir) source for the medical treatment as well as for the industrial using in the non-destructive inspection has been irradiated. As one of effective use of the renewed JMTR, JAEA has a plan to product molybdenum-99 (99Mo), a parent nuclide of technetium-99 (99mTc). 99mTc is most commonly used as a radiopharmaceutical in the field of nuclear medicine. Furthermore, production of radioisotope (RI) for which increasing demand is expected, e.g. rhenium-188 (188Re) which being expected as a cancer treatment medicine. (author)

Part of:
Proceedings of 2008 KAERI/JAEA joint seminar on advanced irradiation and PIE technologies

Additional details

Publishing Information

Imprint Title
Proceedings of 2008 KAERI/JAEA joint seminar on advanced irradiation and PIE technologies
Imprint Pagination
462 p.
Journal Page Range
p. 127-131
Report number
JAEA-Conf--2008-010

Conference

Title
2008 KAERI/JAEA joint seminar on advanced irradiation and PIE technologies
Dates
5-7 Nov 2008
Place
Daejeon (Korea, Republic of)

Optional Information

Notes
5 refs., 2 figs.
Secondary number(s)
KAERI/GP--279-2008